Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET

Company Participants

Carlo Tanzi - IR Officer

Eric Shaff - President and CEO

Lisa von Moltke - EVP and Chief Medical Officer

Terri Young - Chief Commercial Officer

David Arkowitz - EVP, CFO and Head of Business Development

Matthew Henn - Chief Scientific Officer

Conference Call Participants

Joseph Thome - TD Cowen

Edward Tenthoff - Piper Sandler

Tessa Romero - JPMorgan

Operator

Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Seres Therapeutics's Second Quarter Earnings Conference Call. [Operator Instructions]

I would now like to turn the conference over to Dr. Carlo Tanzi, Head of Investor Relations. Please go ahead.

Carlo Tanzi

Thank you, and good morning. Our press release for the Company's second quarter 2023 financial results, and the business update became available at 7.00 AM Eastern Time this morning, and can be found on the investors' news section of the company's website.

I'd like to remind you that we will be making forward-looking statements, including the commercial success of the house, the timing and results of clinical studies, the ability for microbiome therapeutics to modulate the microbiome and treat or prevent infection, our ability to achieve sales targets and the receipt of future milestones and debt tranches, and other statements which are not historical fact. Actual results may differ materially.

Additionally, these statements are subject to certain risks and uncertainties which are discussed under the risk-pecker section of our recent SEC filings. Any forward-looking statements made on today's call, or represent our views as of today only. We may update these statements in the future, but we disclaim any obligations to do so.

On today's call, with prepared remarks, I'm joined by Eric Shaff, Seres' President and CEO; Dr. Lisa von Moltke, Chief Medical Officer; and Dr. Terri Young, Chief Commercial Officer; and David Arkowitz, Chief Financial Officer, in addition Dr. Matthew Henn, Chief Scientific Officer, will also be available to answer your questions.

With that, I'll have to call to Eric.

Eric Shaff

Thank you, Carlos, and good morning, everyone. This has been a monumental period for Seres. Indeed, based on the progress we have made developing a microbiome therapeutics as a new medical category, Seres was recently nominated as a member of the Time100 Most Influential Companies for 2023 within the Pioneer's category.